FMCQF:OTC-Fresenius Medical Care AG & Co. KGaA (USD)

COMMON STOCK | Medical Care Facilities |

Last Closing

USD 39.7

Change

0.00 (0.00)%

Market Cap

USD 12.25B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
FSNUF Fresenius SE & Co. KGaA

N/A

USD 20.89B
BDUUY Bangkok Dusit Medical Services..

N/A

USD 13.86B
RMYHY Ramsay Health Care Ltd ADR

-0.36 (-5.40%)

USD 6.16B
HYHHF Hygeia Healthcare Holdings Co ..

N/A

USD 3.14B
RYHTY Ryman Healthcare Ltd ADR

-0.43 (-2.99%)

USD 2.06B
AEVIF Aevis Victoria SA

N/A

USD 1.69B
DNTCF dentalcorp Holdings Ltd.

N/A

USD 1.16B
RHKJF RHÖN-KLINIKUM Aktiengesellsch..

N/A

USD 0.82B
PFSMF Perfect Medical Health Managem..

N/A

USD 0.70B
EXETF Extendicare Inc

+0.13 (+1.90%)

USD 0.56B

ETFs Containing FMCQF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.27% 53% F 49% F
Dividend Return 3.12% 43% F 51% F
Total Return -1.15% 50% F 49% F
Trailing 12 Months  
Capital Gain -8.10% 54% F 49% F
Dividend Return 2.99% 50% F 43% F
Total Return -5.11% 54% F 50% F
Trailing 5 Years  
Capital Gain -43.00% 66% D+ 41% F
Dividend Return 12.05% 64% D 42% F
Total Return -30.95% 66% D+ 45% F
Average Annual (5 Year Horizon)  
Capital Gain -10.82% 39% F 21% F
Dividend Return -7.94% 44% F 23% F
Total Return 2.88% 62% D 51% F
Risk Return Profile  
Volatility (Standard Deviation) 26.32% 81% B- 78% C+
Risk Adjusted Return -30.17% 39% F 21% F
Market Capitalization 12.25B 96% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector